1
|
Zhang L, Zheng X, Bai X, Wang Q, Chen B, Wang H, Lu J, Hu S, Zhang X, Zhang H, Liu J, Shi Y, Zhou Z, Gan L, Li X, Li J. Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: A national retrospective registry study. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2021; 85:153531. [PMID: 33799224 PMCID: PMC7914374 DOI: 10.1016/j.phymed.2021.153531] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Revised: 02/11/2021] [Accepted: 02/23/2021] [Indexed: 05/20/2023]
Abstract
BACKGROUND Qingfei Paidu Tang (QPT), a formula of traditional Chinese medicine, which was suggested to be able to ease symptoms in patients with Coronavirus Disease 2019 (COVID-19), has been recommended by clinical guidelines and widely used to treat COVID-19 in China. However, whether it decreases mortality remains unknown. PURPOSE We aimed to explore the association between QPT use and in-hospital mortality among patients hospitalized for COVID-19. STUDY DESIGN A retrospective study based on a real-world database was conducted. METHODS We identified patients consecutively hospitalized with COVID-19 in 15 hospitals from a national retrospective registry in China, from January through May 2020. Data on patients' characteristics, treatments, and outcomes were extracted from the electronic medical records. The association of QPT use with COVID-19 related mortality was evaluated using Cox proportional hazards models based on propensity score analysis. RESULTS Of the 8939 patients included, 28.7% received QPT. The COVID-19 related mortality was 1.2% (95% confidence interval [CI] 0.8% to 1.7%) among the patients receiving QPT and 4.8% (95% CI 4.3% to 5.3%) among those not receiving QPT. After adjustment for patient characteristics and concomitant treatments, QPT use was associated with a relative reduction of 50% in-hospital COVID-19 related mortality (hazard ratio, 0.50; 95% CI, 0.37 to 0.66 p < 0.001). This association was consistent across subgroups by sex and age. Meanwhile, the incidences of acute liver injury (8.9% [95% CI, 7.8% to 10.1%] vs. 9.9% [95% CI, 9.2% to 10.7%]; odds ratio, 0.96 [95% CI, 0.81% to 1.14%], p = 0.658) and acute kidney injury (1.6% [95% CI, 1.2% to 2.2%] vs. 3.0% [95% CI, 2.6% to 3.5%]; odds ratio, 0.85 [95% CI, 0.62 to 1.17], p = 0.318) were comparable between patients receiving QPT and those not receiving QPT. The major study limitations included that the study was an observational study based on real-world data rather than a randomized control trial, and the quality of data could be affected by the accuracy and completeness of medical records. CONCLUSIONS QPT was associated with a substantially lower risk of in-hospital mortality, without extra risk of acute liver injury or acute kidney injury among patients hospitalized with COVID-19.
Collapse
Affiliation(s)
- Lihua Zhang
- National Clinical Research Center for Cardiovascular Diseases, State Key, Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for, Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing, People's Republic of China
| | - Xin Zheng
- National Clinical Research Center for Cardiovascular Diseases, State Key, Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for, Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing, People's Republic of China
| | - Xueke Bai
- National Clinical Research Center for Cardiovascular Diseases, State Key, Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for, Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing, People's Republic of China
| | - Qing Wang
- National Clinical Research Center for Cardiovascular Diseases, State Key, Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for, Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing, People's Republic of China
| | - Bowang Chen
- National Clinical Research Center for Cardiovascular Diseases, State Key, Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for, Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing, People's Republic of China
| | - Haibo Wang
- Clinical Trial Unit, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou Province, People's Republic of China
| | - Jiapeng Lu
- National Clinical Research Center for Cardiovascular Diseases, State Key, Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for, Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing, People's Republic of China
| | - Shuang Hu
- National Clinical Research Center for Cardiovascular Diseases, State Key, Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for, Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing, People's Republic of China
| | - Xiaoyan Zhang
- National Clinical Research Center for Cardiovascular Diseases, State Key, Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for, Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing, People's Republic of China
| | - Haibo Zhang
- National Clinical Research Center for Cardiovascular Diseases, State Key, Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for, Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing, People's Republic of China
| | - Jiamin Liu
- National Clinical Research Center for Cardiovascular Diseases, State Key, Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for, Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing, People's Republic of China
| | - Ying Shi
- China Standard Medical Information Research Center, Shenzhen, People's Republic of China
| | - Zhiye Zhou
- China Standard Medical Information Research Center, Shenzhen, People's Republic of China
| | - Lanxia Gan
- China Standard Medical Information Research Center, Shenzhen, People's Republic of China
| | - Xi Li
- National Clinical Research Center for Cardiovascular Diseases, State Key, Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for, Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing, People's Republic of China; Central China Subcenter of the National Center for Cardiovascular Diseases, Zhengzhou, People's Republic of China.
| | - Jing Li
- National Clinical Research Center for Cardiovascular Diseases, State Key, Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for, Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing, People's Republic of China; Central China Subcenter of the National Center for Cardiovascular Diseases, Zhengzhou, People's Republic of China; Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
| |
Collapse
|
2
|
Wang T, Lu M, Du Q, Yao X, Zhang P, Chen X, Xie W, Li Z, Ma Y, Zhu Y. An integrated anti-arrhythmic target network of a Chinese medicine compound, Wenxin Keli, revealed by combined machine learning and molecular pathway analysis. MOLECULAR BIOSYSTEMS 2017; 13:1018-1030. [DOI: 10.1039/c7mb00003k] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Deciphering the compound Wenxin Keli's anti-arrhythmic pharmacological mechanism by integrating network pharmacology and experimental verification methods.
Collapse
|
3
|
Addition and Subtraction Theory of TCM Using Xiao-Chaihu-Decoction and Naturopathy in Predicting Survival Outcomes of Primary Liver Cancer Patients: A Prospective Cohort Study. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2016; 2016:4723530. [PMID: 27843477 PMCID: PMC5098078 DOI: 10.1155/2016/4723530] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Revised: 08/20/2016] [Accepted: 08/29/2016] [Indexed: 01/01/2023]
Abstract
To investigate the therapeutic effect of combined Xiao-Chaihu-Decoction and naturopathic medicine therapy on survival outcomes of patients' PLC. In XCHD group (n = 76), patients were treated with Xiao-Chaihu-Decoction in accordance with the addition and subtraction theory of TCM; in NM group (n = 89), patients were managed by naturopathic medicine; in combined group (n = 70), the same volume of Xiao-Chaihu-Decoction combined with naturopathic medicine procedures was applied. There were no evident statistical differences of age, gender, KPS score, body weight, smoking status, AFP levels, HbsAg status, TBIL levels, tumor diameters, and numbers among different groups, showing comparability among groups. No significant difference was found regarding the total remission rate and stability rate of tumors in patients treated by Xiao-Chaihu-Decoction and naturopathic medicine, except the combined therapy. KPS scores were significantly improved after treatment among groups. After treatment, 52.8% cases maintained a stable or slight increase in weight, of which 42.1%, 48.3%, and 70.0% cases maintained weight stably in the XCHD group, NM group, and combined treatment group, respectively. Xiao-Chaihu-Decoction associated with naturopathy may predict improved prognostic outcomes in PLC patients, along with improved remission and stability rates, increased KPS scores, and stable weight maintenance.
Collapse
|
5
|
Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z, Han J. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends 2015; 9:16-34. [PMID: 25787906 DOI: 10.5582/bst.2015.01019] [Citation(s) in RCA: 281] [Impact Index Per Article: 31.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Recent studies indicate that Traditional Chinese medicine (TCM) can play an important role in the whole course of cancer treatment such as recovery stages of post-operative, radiotherapy or chemotherapy stages instead of only terminal stage of cancer. In this review, we have summarized current evidence for using TCM as adjuvant cancer treatment in different stages of cancer lesions. Some TCMs (e.g., TJ-41, Liu-jun-zi-tang, PHY906, Coumarin, and Aescine) are capable of improving the post-operative symptoms such as fatigue, pain, appetite, diarrhea, nausea, vomiting, and lymphedema. Some TCMs (e.g., Ginseng, Huang-Qi, BanZhiLian, TJ-48, Huachansu injection, Shenqi fuzheng injection, and Kanglaite injection) in combination with chemo- or radio-therapy are capable of enhancing the efficacy of and diminishing the side effects and complications caused by chemo- and radiotherapy. Taken together, they have great advantages in terms of suppressing tumor progression, relieving surgery complications, increasing the sensitivity of chemo- and radio- therapeutics, improving an organism's immune system function, and lessening the damage caused by surgery, chemo- or radio-therapeutics. They have significant effects on relieving breast cancer-related lymphedema, reducing cancer-related fatigue and pain, improving radiation pneumonitis and gastrointestinal side effects, protecting liver function, and even ameliorating bone marrow suppression. This review of those medicines should contribute to an understanding of Chinese herbal medicines as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer, by providing useful information for development of more effective anti-cancer drugs and making more patients "survival with cancer" for a long time.
Collapse
Affiliation(s)
- Fanghua Qi
- Department of Traditional Chinese Medicine, Shandong Provincial Hospital affiliated to Shandong University
| | | | | | | | | | | | | |
Collapse
|